et al.. Betaadrenergic and atrial natriuretic peptide interactions on human cardiovascular and metabolic regulation.. Abstract Context: Atrial natriuretic peptide (ANP) has well known cardiovascular effects and modifies lipid and carbohydrate metabolism in humans. Objective: To determine the metabolic and cardiovascular interaction of beta-adrenergic receptors and ANP. Design: Cross over study, conducted 2004-2005 Setting: Academic clinical research center Patients: Ten healthy, young, male subjects (BMI 24±1 kg/m²) Intervention: We infused intravenously incremental ANP doses (6.25, 12.5, and 25 ng/kg/min) with and without propranolol (0.20 mg/kg in divided doses followed by 0.033 mg/kg/h infusion). Metabolism was monitored through venous blood sampling, intramuscular and subcutaneous microdialysis and indirect calorimetry. Cardiovascular changes where monitored by continuous ECG and beat-by-beat blood pressure recordings. Main outcome measures: Venous NEFA, glycerol, glucose, insulin; microdialysate glucose, glycerol, lactate, pyruvate. Results: ANP increased heart rate dose dependently. Beta-adrenergic receptor blockade abolished the response. ANP elicited a dose-dependent increase in serum non-esterified fatty acid and glycerol concentrations. The response was not suppressed with propranolol. Venous glucose and insulin concentrations increased with ANP, both, without or with propranolol.
Introduction
Atrial natriuretic peptide (ANP) is synthesized within the heart in response to myocardial stretch. ANP has well characterized cardiovascular effects including regulation of vascular tone, renal sodium handling, and myocardial hypertrophy. (1) Recent studies suggest that ANP also influences lipid and carbohydrate metabolism, thus providing a link between metabolic and cardiovascular regulation. ANP stimulates lipolysis in vitro in human adipocytes(2;3) and locally in subcutaneous adipose tissue. (2) Systemic ANP infusion in pharmacological (4;5) and physiological concentrations, (6) dose-dependently increase circulating non-esterified fatty acid (NEFA) and glycerol concentrations. Moreover, ANP might be involved in the control of lipid mobilization during exercise. (7;8) The in vitro studies suggest that ANP induced lipolysis is mediated through natriuretic peptide receptor A (NPrA) activation. NPrA stimulates hormone-sensitive lipase through the cGMP pathway.(3;9) Activated hormone-sensitive lipase cleaves triacylglycerides into NEFA and glycerol. Generally, lipolysis is regulated by the sympathetic nervous system. It is possible that metabolic responses to systemic ANP infusions are mediated through the sympathetic nervous system rather than NPrA activation. Indeed, the ANP mediated reduction in blood pressure may cause baroreflex mediated increases in sympathetic nervous activity. Larger ANP concentrations increase norepinephrine concentrations, heart rate,(6;10) muscle sympathetic nerve activity,(10) and regional vascular resistance. (11) Yet, ANP may also have a direct sympatholytic effect. (10;12) In a previous study, local glycerol concentrations were not reduced by local beta-adrenergic receptor blockade applied via microdialysis. (5) However, local beta-adrenergic receptor blockade does not exclude the possibility that ANPinduced metabolic changes are secondary to reflex-mediated beta-adrenergic receptor stimulation. We tested the hypothesis that ANP induced changes in glucose and lipid metabolism, in particular adipose tissue lipolysis, are secondary to beta-adrenergic receptor stimulation.
Materials and Methods
Subjects. We studied 10 healthy men (age 32±2 yr, body mass index, 24±1 kg/m 2 , waist to hip ratio, 0.82 ±0.05). They received no medications. Human subcutaneous adipose tissue for in vitro experiments was obtained from 6 moderately overweight women undergoing plastic surgery (34±1 years, BMI 26±1 kg/m 2 ).Written informed consent was obtained before study entry. The institutional review board approved all studies including sampling of adipocytes from surgical specimen.
Protocol. Subjects abstained from smoking, alcohol ingestion, caffeine-containing beverages, and vigorous exercise 48 hours before the experiments. We conducted all experiments in the morning after an overnight fast. Probands remained supine throughout the experiment. ANP was infused on two separate days, either with or without the non-selective beta-adrenergic receptor blocker propranolol in a cross over fashion. The washout phase between experiments was at least seven days. After a resting phase of 30 minutes, we obtained baseline indirect calorimetric measurements over a 30 minute period. Then, we removed the ventilated hood, and started incremental human ANP infusions (Merck Bioscience AG, Clinalfa, Switzerland). We infused ANP at rates of 6.25, 12.5, and 25 ng/kg/min for 45 minutes each. These infusion rates have previously been shown to provide physiological to pathophysiological venous ANP concentrations in humans. (6) The duration of each infusion was sufficient to attain the maximal ANP mediated lipolytic effect of each dose. (5) We repeated indirect calorimetry measurements during the last 30 minutes of each ANP-infusion step. When the non-selective beta-adrenergic receptor blocker propranolol was applied in combination with ANP, it was given as follows: 0.2 mg/kg intravenously in four divided bolus doses before ANP infusion followed by continuous propranolol infusion with 0.033mg/kg/h throughout the experiment. These doses have previously been shown to completely inhibit isoproterenol induced lipolysis.(13) Venous blood and microdialysis samples were collected at baseline and every 15 minutes of ANP infusion.
Instrumentation: Before resting phase, two venous catheters (Vasocan, 20G, B. Braun, Germany) were placed in large antecubital veins of both arms. Infusions and blood sampling were performed on contra lateral arms. One microdialysis probe (CMA60) each was inserted into abdominal subcutaneous adipose tissue (SCAT) and into femoral skeletal muscle (quadriceps femoris, vastus lateralis) as described previously. (14;15) Respiration and ECG were measured continuously (Cardioscreen, Medis GmbH). Beat-by-beat finger blood pressure (Finapres, Ohmeda, USA) was recorded continuously throughout experiments.
Brachial arterial blood pressure (Dinamap, Critikon, USA) was determined automatically every 5 minutes contra laterally to the infusion side. We used a ventilated hood to monitor O 2 consumption and CO 2 production (DeltatracII, Datex Ohmeda, Germany) by indirect calorimetry to assess energy expenditure and substrate oxidation rates. Whole-body carbohydrate-and fat-oxidation rates were estimated using stoechiometric equations(16).
Microdialysis: Details of the microdialysis-technique are described elsewhere. (14;15) Briefly, before insertion of the probes, we applied a local anesthetic (lidocaine) either as a cream for adipose tissue (EMLA, Astra GmbH, Germany) or as a subcutaneous injection for muscle (Xylocitin 1%, Jenapharm GmbH, Germany). After probe insertion, we started the tissue perfusion with lactate free Ringer solution (Serumwerk Bernburg AG, Germany) at a flow rate of 2 µL/min. The solution was supplemented with 50 mmol/L ethanol (EtOH, B.
Braun Melsungen AG, Germany). CMA/60 microdialysis catheters and CMA/102 microdialysis pumps (both from CMA Microdialysis AB, Sweden) were used. A 60 minute period was allowed for tissue recovery and for baseline calibration. Two 15 minute dialysate fractions were collected at baseline.
Analytical methods. Venous and in vitro glycerol concentrations were determined by an ultra sensitive radiometric method as described previously(6) Venous NEFA were assayed with an enzymatic method (Wako kit, Unipath), insulin concentrations were measured using a radioimmunoassay (Sanofi Diagnostics Pasteur, France In vitro experiments: Adipocytes were isolated by collagenase digestion as described previously (3) After digestion, the suspension was filtered (210-µm filter) and washed 3 times with PBS. Then, adipocytes were brought to a suitable dilution (2000-3000 cells/100 µl) into Krebs Ringer Bicarbonate Hepes 10 mmol/L buffer containing glucose (5.55 mmol/L) and 20 mg/mL of BSA at pH 7.4. Then, adipocytes were incubated during 90 minutes with increasing propranolol concentrations, namely 10 -6 , 10 -5 and 10 -4 mol/L, in presence of 100 nmol/L isoproterenol or ANP at 37°C under gentle shaking at 120 cycles/min in a water bath. After incubation, 50 µl of medium were taken to measure glycerol and total lipids were extracted gravimetrically as described previously (3) .
Calculations and statistics: All data are expressed as mean±SEM. Repeated-measures ANOVA testing was used for multiple comparisons. Bonferoni's post hoc test was performed, when P<0.05. A value of P<0.05 was considered significant.
Results
All subjects tolerated ANP and propranolol infusions well. Three probands had to be excluded from the analysis after experiments had been performed. One proband showed raised venous glucose concentrations at baseline on one of the study days suggesting that he was not in the fasted state. In the second proband, NEFA measurements at baseline differed more than twofold on both study days. In the third subject, several venous measurements including NEFA could not be obtained at baseline and on different time points during drug infusion. In our analysis, we only included seven subjects with a full data set.
Hemodynamic responses: With ANP infusions, heart rate increased dose dependently from 56±1 beats per minute (bpm) at baseline to 72±2 bpm at the highest ANP infusion rate (p<0.01). With the combination of ANP and propranolol, heart rate was 56±1 bpm at baseline and did not increase over time (p<0.001 for the propranolol effect) (figure 1a). Heart rate variability is displayed in detail in table 1. Heart rate variability in the time domain decreased substantially during ANP infusion. Furthermore, we observed a reduction in heart rate variability in the low frequency and in the high frequency domain with incremental ANP infusion. Propranolol attenuated ANP induced changes in heart rate variability. However, the ANP induced reduction in heart rate variability was not fully suppressed with propranolol.
With ANP infusion, blood pressure was 118±3/61±3 mm Hg at baseline and 114±4/59±3 mm Hg at the highest ANP infusion rate (ns). With the combination of ANP and propranolol, blood pressure was 116 ±3/68±3 mm Hg at baseline and 106±4/59±3 mm Hg at the highest ANP infusion rate (p=0.06). Mean arterial blood pressure is displayed in figure 1b.
Venous measurements: With ANP infusions, venous NEFA and glycerol concentrations increased dose dependently ( Fig.2 a, b) . The response was not attenuated with propranolol. ANP increased glucose, without or with propranolol ( Fig. 1 c) . Without propranolol, insulin was 4.2±0.6 µU/mL at baseline, 4.80±0.9 µU/mL at an infusion rate of 6.25 ng/kg/min, 5.3±1.2 µU/mL at an infusion rate of 12.5 ng/kg/min, and 5.7±0.6 at the highest ANP infusion rate (p=0.06 vs baseline). With the combination of ANP and propranolol, venous insulin concentrations were 4.7 µU/mL at baseline, 4.2±0.5 mU/mL at the lowest ANP-infusion rate, 4.3±0.2 µU/mL at an infusion rate of 12.5 ng/kg/min, and 5.7±0.6 µU/mL at the highest infusion rate (ns for propranolol effect).
Microdialysis: Adipose tissue ethanol ratio and glucose concentrations are given in table 1. In abdominal subcutaneous adipose tissue (SCAT), the ethanol ratio tended to decrease with and without propranolol. SCAT glucose and lactate concentrations increased without (p<0.05) and with propranolol (p<0.01) at the highest ANP infusion rate ( Fig. 3b ) (ns for propranolol effect). With ANP, the maximal increase in SCAT glycerol concentrations was 36% (p < 0.05) with ANP, and 54% (p<0.01) with the combination of ANP and propranolol at the highest ANP infusion rate (ns for propranolol effect) ( Fig. 3a) .
In skeletal muscle, the ethanol ratio did not change during ANP infusions with and without propranolol. Similarly, ANP did not change dialysate glucose concentrations. Yet, dialysate lactate concentrations maximally increased by 25% (p<0.001) with ANP and by 32% (p<0.05) with ANP and propranolol ( Fig. 3d ) (ns for propranolol effect). Dialysate pyruvate concentration increased to a maximum of 530% (p<0.001) with ANP and 670% (p<0.001) with ANP and propranolol (p<0.001) (ns for propranolol effect). The lactate to pyruvate ratio decreased with ANP from 103±43 at baseline to 24±3 (p<0.001) at the highest ANP infusion rate and from 354±272 at baseline to 43±14 (p<0.001) at the highest ANP infusion rate with propranolol (ns for propranolol effect). The numerical difference in the lactate to pyruvate ratio with and without propranolol was solely explained by a single proband with an unusually low pyruvate measurement on propranolol. Skeletal muscle dialysate glycerol concentrations did not change throughout the ANP infusion (Fig. 3c ).
Indirect calorimetry: Resting energy expenditure did not change significantly with ANP or with the combination of ANP and propranolol (figure 4 a). The respiratory quotient tended to increase above baseline at an ANP infusion rate of 6.25 ng/kg/min, but decreased below baseline as infusion rate was further increased (figure 4 b) . Accordingly, carbohydrate oxidation rate increased by 45% above baseline at an ANP infusion rate of 6.25 ng/kg/min, and decreased by 30% below baseline at an ANP infusion rate of 25 ng/kg/min (p<0.05 vs 6.25 ng/kg/min). Without propranolol, lipid oxidation rate tended to decrease below baseline at an ANP infusion rate of 6.25 ng/kg/min, while it increased to a maximum of 34% above baseline with the highest ANP infusion rate (p<0.05 vs baseline). The biphasic response of lipid oxidation rate was attenuated with propranolol. We calculated the amplitude of the change in lipid oxidation rate as the difference between maximal lipid oxidation rate and minimal lipid oxidation rate in each subject. The amplitude was 13±1.3 g/6h without propranolol and 7±1.9 g/6h with propranolol (p<0.05).
In vitro experiments: Figure 5 illustrates changes in glycerol concentrations with isoproterenol and ANP in the presence and in the absence of propranolol in human mature adipocytes. Isoproterenol increased glycerol release substantially. The response was abolished with 1 µmol/L propranolol. Larger propranolol concentrations decreased glycerol concentrations below the baseline value. In contrast, the ANP driven glycerol release from isolated adipocytes was not attenuated with propranolol. The relative decrease in glycerol with ANP and the highest propranolol concentration is equivalent to the decrease in glycerol values below baseline with isoproterenol and the highest propranolol concentration.
Discussion
We conducted in vitro and in vivo experiments to study the interaction of ANP and beta-adrenergic receptors on human metabolism and cardiovascular regulation. The main finding of our study is that propranolol attenuated the ANP induced changes in heart rate and in heart rate variability. In contrast, ANP induced changes in lipolysis and carbohydrate metabolism were not attenuated with propranolol. Initially, we tested the effect of isoproterenol and ANP on in vitro lipolysis, both in the presence and in the absence of propranolol. Adipocytes exhibited a strong lipolytic response to isoproterenol and to ANP. Possibly, ANP increased sympathetic outflow to adipose tissue. To address this issue, we applied incremental intravenous ANP concentrations in humans, both in the absence and in the presence of near-complete systemic beta-adrenergic receptor blockade with propranolol. Propranolol in doses applied here abolishes the lipolytic response to local isoproterenol infusion.(13) Similar to earlier studies,(6) ANP increased circulating NEFA and glycerol concentrations. In the present study, systemic beta-adrenergic receptor blockade did not attenuate the response. To further address the interaction between ANP and betaadrenergic mechanisms on lipolysis, we assessed adipose tissue and skeletal muscle metabolism using microdialysis. We observed a tissue-specific ANP effect on lipolysis.
Local concentrations of glycerol in adipose tissue increased markedly with ANP. The response was not abolished with propranolol. In contrast, ANP in skeletal muscle did not increase glycerol concentrations. Our observations, together with previous studies using local beta-adrenoreceptor blockade, (5) pnn50 = proportion of successive normal-to-normal intervals differences greater than 50 msec, hf rri = RR variability in the high frequency range, lf rri = RR variability in the low frequency range, *=p<0.05 ANP vs ANP&propranolol
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